<p class="MsoNormal">US-based biopharmaceutical company Gilead Sciences Inc on Thursday said it will acquire German biotechnology firm MYR GmbH for around $1.39 billion in cash. The acquisition will provide Gilead access to MYR’s treatment for a severe form of viral hepatitis. The deal also includes a potential future milestone payment of up to $363.60 million.</p>
